A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary Intervention.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2239
Abstract: To compare the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) treated with primary percutaneous coronary intervention (PPCI). 3,528 consecutive patients with ACS treated with PPCI were divided into… read more here.
Keywords: ticagrelor; ticagrelor clopidogrel; clopidogrel patients; clopidogrel ... See more keywords
One- and five-year mortality according to first use of ticagrelor or clopidogrel at the acute stage of myocardial infarction in elderly patients: the FAST-MI 2015 registry
Sign Up to like & getrecommendations! Published in 2024 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehae666.3127
Abstract: Guidelines recommend ticagrelor over clopidogrel in patients with AMI, irrespective of their age. The PLATO trial, which showed lower mortality with ticagrelor, included only few very elderly patients. To analyze one- and 5-year outcomes according… read more here.
Keywords: use ticagrelor; year; ticagrelor; ticagrelor clopidogrel ... See more keywords
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehae666.3345
Abstract: Acute coronary syndrome (ACS) represents a significant health burden, especially in elderly patients. Antiplatelet therapy forms the cornerstone of medical treatment for ACS, prasugrel and ticagrelor are preferred for their rapid action and proven efficacy.… read more here.
Keywords: mortality; ticagrelor; ticagrelor clopidogrel; prasugrel ticagrelor ... See more keywords
Abstract 4136210: Meta-Analysis of Efficacy and Safety in DAPT De-escalation: Transitioning from Ticagrelor to Clopidogrel in Acute Myocardial Infarction Following Percutaneous Coronary Intervention at twelve-Month Follow-Up
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4136210
Abstract: Background: In the management of acute myocardial infarction (AMI) following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) plays a crucial role in preventing recurrent ischemic events. Recent studies have explored the feasibility and safety… read more here.
Keywords: following percutaneous; myocardial infarction; acute myocardial; ticagrelor ... See more keywords
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study
Sign Up to like & getrecommendations! Published in 2018 at "Circulation"
DOI: 10.1161/circulationaha.118.033983
Abstract: Background: Switching between different classes of P2Y12 inhibitors, including de-escalation from ticagrelor to clopidogrel, commonly occurs in clinical practice. However, the pharmacodynamic profiles of this strategy have been poorly explored. Methods: This was a prospective,… read more here.
Keywords: ticagrelor clopidogrel; platelet; group; 24h group ... See more keywords
A comparison of the effects of ticagrelor and clopidogrel in patients with acute ST-segment elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials
Sign Up to like & getrecommendations! Published in 2024 at "BMC Pharmacology & Toxicology"
DOI: 10.1186/s40360-024-00817-8
Abstract: Rupture of unstable coronary atherosclerotic plaque leads to acute ST-segment elevation myocardial infarction (STEMI). Dual anti-platelet therapy is one of the main treatments, and the combination of Aspirin and Clopidogrel is recognized as the standard… read more here.
Keywords: infarction; ticagrelor clopidogrel; myocardial infarction; meta analysis ... See more keywords
Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-22-740
Abstract: Background Clopidogrel is a traditional P2Y12 receptor inhibitor that is widely used in clinical practice, but there are significant individual differences in its therapeutic effect. Carriers of the CYP2C19 deletion allele have a higher risk… read more here.
Keywords: ticagrelor; prognosis; ticagrelor clopidogrel; disease ... See more keywords
Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2023.1143509
Abstract: Background Current guidelines recommend potent P2Y12 inhibitors for patients after acute coronary syndrome. However, the data on the efficacy and safety of potent P2Y12 inhibitors in elderly Asian populations was limited. We aimed to investigate… read more here.
Keywords: elderly asian; ticagrelor; ticagrelor clopidogrel; clopidogrel ... See more keywords
Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.970066
Abstract: Background: Ticagrelor and clopidogrel are commonly used antiplatelet agents, and we conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) to provide a reference for safe and reasonable clinical… read more here.
Keywords: ticagrelor; ror prr; ticagrelor clopidogrel; hemorrhagic signals ... See more keywords
Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
Sign Up to like & getrecommendations! Published in 2019 at "Turkish Journal of Medical Sciences"
DOI: 10.3906/sag-1903-188
Abstract: Background/aim Ticagrelor is a drug widely used in patients with acute coronary syndromes (ACS) that specifically increases the plasma level of adenosine, which is likely to cause atrial fibrillation (AF). Therefore, in this study we… read more here.
Keywords: atrial fibrillation; clopidogrel; patients acute; ticagrelor clopidogrel ... See more keywords
DAPT de-escalation from ticagrelor to clopidogrel 1 mo after PCI for acute MI reduced net clinical events at 1 y
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0002
Abstract: SOURCE CITATION Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.… read more here.
Keywords: ticagrelor clopidogrel; escalation ticagrelor; dapt escalation;